Amgen is a leading biotechnology company that focuses on the development, manufacturing, and commercialization of innovative therapeutic solutions to treat serious illnesses. The company leverages its advanced science and research capabilities to create biologic therapies that target various medical conditions, including cancer, kidney disease, and rheumatoid arthritis. Through a commitment to scientific excellence, Amgen aims to enhance patient care by providing effective treatments that improve health outcomes and quality of life. Additionally, the company engages in extensive research collaborations and partnerships, further advancing its mission to deliver groundbreaking therapies to patients around the world. Read More
As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an uncertain economic landscape. While specific real-time data for this future date is beyond current predictive capabilities, an analysis of the sector's
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance, particularly by companies at the forefront of artificial intelligence (AI), tech stocks are now experiencing a noticeable downturn. This
The Nasdaq Composite (NASDAQ: IXIC) experienced back-to-back losses on November 11 and 12, 2025, signaling a significant recalibration in the financial markets. This downturn, primarily driven by growing concerns over stretched valuations in the artificial intelligence (AI) sector and a pronounced rotation of capital into more traditional industries, marks a
New York, NY – November 12, 2025 – The Dow Jones Industrial Average (DJIA) has shattered previous records, closing at an all-time high of 48,254.82 today, marking a significant milestone for the venerable index. This historic surge, following another record close yesterday, injects a palpable sense of optimism into the
The financial markets are currently exhibiting an extraordinary and complex phenomenon: both traditional safe-haven assets, gold and silver, are experiencing robust rallies, while the Dow Jones Industrial Average (DJIA) has simultaneously surged past the 48,000-point mark. As of November 12, 2025, gold prices are trading around $4,105-$4,
New York, NY – November 12, 2025 – In a remarkable display of market resilience and underlying tension, the Dow Jones Industrial Average (DJIA) has surged past the 48,000-point threshold, closing at an unprecedented 48,015.79. This historic equity rally is unfolding concurrently with a robust ascent in precious metals,
The Dow Jones Industrial Average (DJIA) made history on Wednesday, November 12, 2025, surging past the 48,000-point mark for the first time ever, gaining nearly 380 points. This significant rally was fueled by a wave of optimism surrounding the imminent resolution of a protracted U.S. government shutdown, which
NEW YORK, NY – November 11, 2025 – The Dow Jones Industrial Average (DJIA) has reached an unprecedented milestone today, soaring to a new all-time high of 47,927.96, a robust gain of 559.33 points (1.2%). This marks the 16th record close for the index this year, sending a
New York, NY – November 11, 2025 – The Dow Jones Industrial Average (DJIA) has today surged to an unprecedented all-time high, pushing past significant milestones and reinforcing a complex, yet largely optimistic, sentiment across the financial markets. This monumental achievement signals a robust, albeit cautious, wave of investor confidence, underpinned by
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
Amgen’s third quarter results were well received by the market, reflecting robust volume-driven growth across its diversified portfolio. Management credited rising demand for key medicines—including Repatha, EVENITY, TEZSPIRE, and its rare disease and biosimilar portfolios—as major contributors to the company’s 12% year-over-year revenue increase. CEO Robert Bradway highlighted, “Volume growth reflects the strength of our portfolio and the value our medicines provide to patients and prescribers.” The quarter also benefited from product launches and expanded access initiatives.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Moderna (NASDAQ:MRNA) and its peers.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
The past week, from November 1st to November 8th, 2025, has witnessed a significant shift in global market sentiment, moving decisively towards a "risk-off" stance. Investors are grappling with heightened volatility and a pervasive sense of unease, as U.S. and international equity markets have experienced broad declines, snapping recent
